Paroxysmal Nocturnal Hemoglobinuria, Pnh Clinical Trials
2 recruiting trials for Paroxysmal Nocturnal Hemoglobinuria, Pnh. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Paroxysmal Nocturnal Hemoglobinuria, Pnh clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Institute of Hematology & Blood Diseases Hospital, China (1), Alexion Pharmaceuticals, Inc. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Ultomiris (drug, 1 trial).
Track Paroxysmal Nocturnal Hemoglobinuria, Pnh trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
National Longitudinal Cohort of Hematological Diseases
Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases,...
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Paroxysmal Nocturnal Hemoglobinuria, Pnh, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Paroxysmal Nocturnal Hemoglobinuria, Pnh, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Paroxysmal Nocturnal Hemoglobinuria, Pnh, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.